Bellevue Group AG Has $43.01 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bellevue Group AG boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 36.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 344,348 shares of the biotechnology company’s stock after purchasing an additional 92,027 shares during the period. Bellevue Group AG’s holdings in Sarepta Therapeutics were worth $43,006,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SRPT. Thrivent Financial for Lutherans increased its stake in shares of Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after buying an additional 37,940 shares during the period. Alkeon Capital Management LLC grew its holdings in Sarepta Therapeutics by 13.4% during the 3rd quarter. Alkeon Capital Management LLC now owns 633,845 shares of the biotechnology company’s stock worth $79,161,000 after acquiring an additional 75,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Sarepta Therapeutics by 1.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company’s stock valued at $76,401,000 after acquiring an additional 6,992 shares during the period. abrdn plc raised its stake in shares of Sarepta Therapeutics by 30.7% during the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after acquiring an additional 101,253 shares during the last quarter. Finally, Mizuho Markets Americas LLC lifted its holdings in shares of Sarepta Therapeutics by 22.3% during the third quarter. Mizuho Markets Americas LLC now owns 399,065 shares of the biotechnology company’s stock worth $49,839,000 after purchasing an additional 72,765 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 3.3 %

Shares of NASDAQ:SRPT opened at $133.34 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25. The business’s 50 day simple moving average is $122.50 and its two-hundred day simple moving average is $131.49. The firm has a market cap of $12.74 billion, a P/E ratio of 106.67 and a beta of 0.81.

Analyst Ratings Changes

A number of analysts recently weighed in on SRPT shares. Needham & Company LLC decreased their price objective on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday. Robert W. Baird decreased their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Citigroup cut their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. UBS Group increased their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Finally, Evercore ISI lowered their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.